253 related articles for article (PubMed ID: 11109896)
1. [Glitazones (thiazolidinedione)].
Ducobu J; Sternon J
Rev Med Brux; 2000 Oct; 21(5):441-6. PubMed ID: 11109896
[TBL] [Abstract][Full Text] [Related]
2. [Evaluation of a thiazolidinedione compound as a new antidiabetic drug].
Toyota T
Nihon Rinsho; 2001 Nov; 59(11):2211-8. PubMed ID: 11712410
[TBL] [Abstract][Full Text] [Related]
3. Troglitazone and related compounds: therapeutic potential beyond diabetes.
Fujiwara T; Horikoshi H
Life Sci; 2000 Oct; 67(20):2405-16. PubMed ID: 11065164
[TBL] [Abstract][Full Text] [Related]
4. Novel insulin sensitizers: pharmacogenomic aspects.
Otto C; Lehrke M; Göke B
Pharmacogenomics; 2002 Jan; 3(1):99-116. PubMed ID: 11966407
[TBL] [Abstract][Full Text] [Related]
5. Glitazones: clinical effects and molecular mechanisms.
Stumvoll M; Häring HU
Ann Med; 2002; 34(3):217-24. PubMed ID: 12173692
[TBL] [Abstract][Full Text] [Related]
6. Rosiglitazone: an agent from the thiazolidinedione class for the treatment of type 2 diabetes.
Cheng-Lai A; Levine A
Heart Dis; 2000; 2(4):326-33. PubMed ID: 11728276
[TBL] [Abstract][Full Text] [Related]
7. Metabolic and additional vascular effects of thiazolidinediones.
Martens FM; Visseren FL; Lemay J; de Koning EJ; Rabelink TJ
Drugs; 2002; 62(10):1463-80. PubMed ID: 12093315
[TBL] [Abstract][Full Text] [Related]
8. Promising new approaches.
Reasner CA
Diabetes Obes Metab; 1999 May; 1 Suppl 1():S41-8. PubMed ID: 11220287
[TBL] [Abstract][Full Text] [Related]
9. [The development of thiazolidinedione drugs as anti-diabetic agents].
Kuzuya T
Nihon Rinsho; 2000 Feb; 58(2):364-9. PubMed ID: 10707559
[TBL] [Abstract][Full Text] [Related]
10. Euglycemic and hypolipidemic activity of PAT5A: a unique thiazolidinedione with weak peroxisome proliferator activated receptor gamma activity.
Vikramadithyan RK; Chakrabarti R; Misra P; Premkumar M; Kumar SK; Rao CS; Ghosh A; Reddy KN; Uma C; Rajagopalan R
Metabolism; 2000 Nov; 49(11):1417-23. PubMed ID: 11092504
[TBL] [Abstract][Full Text] [Related]
11. Hepatotoxicity with thiazolidinediones: is it a class effect?
Scheen AJ
Drug Saf; 2001; 24(12):873-88. PubMed ID: 11735645
[TBL] [Abstract][Full Text] [Related]
12. Insulin resistance and its treatment by thiazolidinediones.
Lebovitz HE; Banerji MA
Recent Prog Horm Res; 2001; 56():265-94. PubMed ID: 11237217
[TBL] [Abstract][Full Text] [Related]
13. Differentiating members of the thiazolidinedione class: a focus on safety.
Lebovitz HE
Diabetes Metab Res Rev; 2002; 18 Suppl 2():S23-9. PubMed ID: 11921435
[TBL] [Abstract][Full Text] [Related]
14. Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence.
Diamant M; Heine RJ
Drugs; 2003; 63(13):1373-405. PubMed ID: 12825962
[TBL] [Abstract][Full Text] [Related]
15. [Mechanisms of action of thiazolidinediones].
Girard J
Diabetes Metab; 2001 Apr; 27(2 Pt 2):271-8. PubMed ID: 11452221
[TBL] [Abstract][Full Text] [Related]
16. Are all glitazones the same?
Van Gaal L; Scheen AJ
Diabetes Metab Res Rev; 2002; 18 Suppl 2():S1-4. PubMed ID: 11921431
[TBL] [Abstract][Full Text] [Related]
17. [Rosiglitazone(BRL-49653)].
Yonezawa N; Oka Y
Nihon Rinsho; 2001 Nov; 59(11):2195-9. PubMed ID: 11712407
[TBL] [Abstract][Full Text] [Related]
18. Role of skeletal muscle in thiazolidinedione insulin sensitizer (PPARgamma agonist) action.
Zierath JR; Ryder JW; Doebber T; Woods J; Wu M; Ventre J; Li Z; McCrary C; Berger J; Zhang B; Moller DE
Endocrinology; 1998 Dec; 139(12):5034-41. PubMed ID: 9832442
[TBL] [Abstract][Full Text] [Related]
19. PPARgamma agonists in the treatment of type II diabetes: is increased fatness commensurate with long-term efficacy?
Larsen TM; Toubro S; Astrup A
Int J Obes Relat Metab Disord; 2003 Feb; 27(2):147-61. PubMed ID: 12586994
[TBL] [Abstract][Full Text] [Related]
20. [Clinical effect and side effect of troglitazone].
Toyota T; Ueno Y
Nihon Rinsho; 2000 Feb; 58(2):376-82. PubMed ID: 10707561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
